S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
Log in

Aevi Genomic Medicine Stock Price, Forecast & Analysis (NASDAQ:GNMX)

$0.13
+0.01 (+8.33 %)
(As of 11/14/2019 04:00 PM ET)
Today's Range
$0.12
Now: $0.13
$0.13
50-Day Range
$0.12
MA: $0.14
$0.17
52-Week Range
$0.11
Now: $0.13
$1.30
Volume954,000 shs
Average Volume1.69 million shs
Market Capitalization$8.42 million
P/E RatioN/A
Dividend YieldN/A
Beta0.64
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMX
Previous SymbolNASDAQ:MDGN
CUSIPN/A
Phone610-254-4201

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.12 per share

Profitability

Net Income$-30,770,000.00

Miscellaneous

Employees14
Market Cap$8.42 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive GNMX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMX and its competitors with MarketBeat's FREE daily newsletter.


Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions

What is Aevi Genomic Medicine's stock symbol?

Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."

How were Aevi Genomic Medicine's earnings last quarter?

Aevi Genomic Medicine Inc (NASDAQ:GNMX) announced its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. View Aevi Genomic Medicine's Earnings History.

When is Aevi Genomic Medicine's next earnings date?

Aevi Genomic Medicine is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Aevi Genomic Medicine.

What is the consensus analysts' recommendation for Aevi Genomic Medicine?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aevi Genomic Medicine in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aevi Genomic Medicine.

Has Aevi Genomic Medicine been receiving favorable news coverage?

Media coverage about GNMX stock has been trending somewhat negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aevi Genomic Medicine earned a news impact score of -1.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Aevi Genomic Medicine.

Are investors shorting Aevi Genomic Medicine?

Aevi Genomic Medicine saw a decline in short interest in October. As of October 31st, there was short interest totalling 911,700 shares, a decline of 9.7% from the September 30th total of 1,010,000 shares. Based on an average daily volume of 591,800 shares, the short-interest ratio is presently 1.5 days. Currently, 2.2% of the shares of the company are sold short. View Aevi Genomic Medicine's Current Options Chain.

Who are some of Aevi Genomic Medicine's key competitors?

What other stocks do shareholders of Aevi Genomic Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aevi Genomic Medicine investors own include Immunomedics (IMMU), Rigel Pharmaceuticals (RIGL), Protalix Biotherapeutics (PLX), Novavax (NVAX), SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Sophiris Bio (SPHS) and Biopharmx (BPMX).

Who are Aevi Genomic Medicine's key executives?

Aevi Genomic Medicine's management team includes the folowing people:
  • Mr. Michael F. Cola, CEO, Pres & Director (Age 59)
  • Mr. Brian D. Piper, CFO & Corp. Sec. (Age 47)
  • Dr. Garry A. Neil, Chief Scientific Officer (Age 65)

How do I buy shares of Aevi Genomic Medicine?

Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aevi Genomic Medicine's stock price today?

One share of GNMX stock can currently be purchased for approximately $0.13.

How big of a company is Aevi Genomic Medicine?

Aevi Genomic Medicine has a market capitalization of $8.42 million. The biotechnology company earns $-30,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Aevi Genomic Medicine employs 14 workers across the globe.View Additional Information About Aevi Genomic Medicine.

What is Aevi Genomic Medicine's official website?

The official website for Aevi Genomic Medicine is http://www.aevigenomics.com/.

How can I contact Aevi Genomic Medicine?

Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]


MarketBeat Community Rating for Aevi Genomic Medicine (NASDAQ GNMX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel